Sara Lonardi

List of Publications by Citations

260 papers	11,685 citations	45 h-index	102 g-index
284 ext. papers	15,293 ext. citations	5.8 avg, IF	5.8 L-index

#	Paper	IF	Citations
260	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncology, The*, **2017**, 18, 1182-1191	21.7	1317
259	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *Journal of Clinical Oncology*, **2018**, 36, 773-779	2.2	938
258	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *New England Journal of Medicine*, **2014**, 371, 1609-18	59.2	663
257	Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *Journal of Clinical Oncology*, **2011**, 29, 2773-80	2.2	597
256	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncology, The*, **2015**, 16, 1306-15	21.7	593
255	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncology, The*, **2015**, 16, 499-508	21.7	568
254	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 738-746	21.7	533
253	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. *New England Journal of Medicine*, **2019**, 381, 1632-1643	59.2	481
252	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 862-73	21.7	190
251	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *British Journal of Cancer*, **2007**, 96, 1047-51	8.7	156
250	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. *Modern Pathology*, **2015**, 28, 1481-91	9.8	144
249	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. *European Journal of Cancer*, **2014**, 50, 57-63	7.5	136
248	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncology*, **2019**, 5, 343-350	13.4	134
247	A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. *Annals of Oncology*, **2005**, 16, 1140-6	10.3	118
246	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. *Annals of Oncology*, **2015**, 26, 1188-1194	10.3	112
245	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. *British Journal of Cancer*, **2015**, 112, 1921-8	8.7	111
244	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2414-2422	12.9	111

243	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 420-435	21.7	110
242	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. *Annals of Oncology*, **2015**, 26, 2092-7	10.3	110
241	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 497-507	21.7	98
240	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 392-8	5.5	91
239	Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. *Annals of Surgical Oncology*, **2011**, 18, 2461-8	3.1	87
238	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. *Annals of Oncology*, **2011**, 22, 1236-1242	10.3	85
237	Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. *Cancer Treatment Reviews*, **2002**, 28, 27-47	14.4	79
236	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. *Cancer Cell*, **2018**, 34, 148-162.e7	24.3	77
235	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. *Hepatology*, **2010**, 51, 165-73	11.2	75
234	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). *Annals of Oncology*, **2013**, 24, 2062-7	10.3	74
233	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. *Oncologist*, **2016**, 21, 988-94	5.7	72
232	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. *Annals of Oncology*, **2014**, 25, 2378-2385	10.3	72
231	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. *Cancer*, **2013**, 119, 3570-7	6.4	69
230	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. *Annals of Oncology*, **2018**, 29, 924-930	10.3	60
229	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. *Digestive and Liver Disease*, **2016**, 48, 231-41	3.3	60
228	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. *Annals of Oncology* , **2018**, 29, 1528-1534	10.3	58
227	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. *Pharmacogenomics Journal*, **2013**, 13, 403-9	3.5	57
226	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. *British Journal of Cancer*, **2014**, 110, 2165-9	8.7	56

225	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. *Annals of Oncology*, **2012**, 23, 3116-3122	10.3	56
224	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. *PLoS ONE*, **2013**, 8, e66774	3.7	55
223	Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. *Annals of Surgical Oncology*, **2012**, 19, 3089-96	3.1	54
222	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. *Annals of Oncology*, **2019**, 30, 1466-1471	10.3	53
221	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. *JAMA Oncology*, **2018**, 4, 529-536	13.4	51
220	Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. *British Journal of Cancer*, **2013**, 108, 278-84	8.7	51
219	Adjuvant chemotherapy in the treatment of high grade gliomas. *Cancer Treatment Reviews*, **2005**, 31, 79-89	14.4	51
218	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. *International Journal of Cancer*, **2015**, 137, 2971-80	7.5	48
217	Immunotherapy in Gastrointestinal Cancers. *BioMed Research International*, **2017**, 2017, 4346576	3	45
216	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. *World Journal of Gastroenterology*, **2019**, 25, 5773-5788	5.6	45
215	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. *Oncologist*, **2019**, 24, 1395-1402	5.7	45
214	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. *Oncologist*, **2020**, 25, 481-487	5.7	43
213	Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. *Supportive Care in Cancer*, **2010**, 18, 601-8	3.9	43
212	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. *Journal of Clinical Oncology*, **2017**, 35, 519-519	2.2	42
211	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. *Journal of Clinical Oncology*, **2021**, 39, 966-977	2.2	42
210	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. *Journal of Clinical Oncology*, **2018**, 36, 1478-1485	2.2	41
209	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. *Annals of Oncology*, **2016**, 27, 2082-2090	10.3	40
208	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. *Journal of Experimental and Clinical Cancer Research*, **2015**, 34, 156	12.8	40

207	Safety and Tolerability of c-MET Inhibitors in Cancer. *Drug Safety*, **2019**, 42, 211-233	5.1	40
206	Gastric cancer: Translating novels concepts into clinical practice. *Cancer Treatment Reviews*, **2019**, 79, 101889	14.4	39
205	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 1069-77	4.9	38
204	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2019**, 5, 1268-1275	13.4	37
203	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. *British Journal of Cancer*, **2014**, 111, 25-32	8.7	37
202	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. *Clinical Cancer Research*, **2019**, 25, 3954-3961	12.9	36
201	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. *Annals of Oncology*, **2016**, 27, 843-9	10.3	36
200	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. *Journal of Clinical Oncology*, **2019**, 37, 3099-3110	2.2	35
199	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. *ESMO Open*, **2020**, 5, e000911	6	35
198	Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. *British Journal of Cancer*, **2017**, 117, 1269-1277	8.7	34
197	Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. *Annals of Oncology*, **2016**, 27, 2074-2081	10.3	33
196	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. *Cancer*, **2012**, 118, 1523-32	6.4	32
195	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. *Annals of Oncology*, **2017**, 28, 555-561	10.3	32
194	Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. *Annals of Oncology*, **2018**, 29, 1955-1963	10.3	31
193	Immune senescence and cancer in elderly patients: results from an exploratory study. *Experimental Gerontology*, **2013**, 48, 1436-42	4.5	31
192	Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. *European Journal of Surgical Oncology*, **2006**, 32, 1201-8	3.6	31
191	Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. *Annals of Oncology*, **2002**, 13, 1882-92	10.3	31
190	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*, **2018**, 23, 1178-1187	5.7	31

189	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. *Journal of Vascular and Interventional Radiology*, **2017**, 28, 1495-1502	2.4	30
188	Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.. *Journal of Clinical Oncology* , **2020**, 38, 11-11	2.2	30
187	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist*, **2015**, 20, 1261-5	5.7	29
186	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. *Expert Review of Anticancer Therapy*, **2018**, 18, 251-266	3.5	29
185	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *European Journal of Cancer*, **2019**, 118, 121-130	7.5	29
184	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. *Scientific Reports*, **2014**, 4, 6828	4.9	29
183	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. *Cancer Chemotherapy and Pharmacology*, **2012**, 70, 899-902	3.5	29
182	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. *Journal of Clinical Oncology*, **2021**, JCO2101015	2.2	29
181	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. *Annals of Oncology*, **2019**, 30, 124-131	10.3	29
180	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. *European Journal of Cancer*, **2017**, 82, 16-24	7.5	28
179	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. *Journal of the Peripheral Nervous System*, **2015**, 20, 15-23	4.7	28
178	Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. *Annals of Oncology*, **2003**, 14, 1727-31	10.3	27
177	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. *Journal of Clinical Oncology*, **2021**, 39, 642-651	2.2	27
176	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. *BMC Cancer*, **2020**, 20, 683	4.8	26
175	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. *European Journal of Cancer*, **2019**, 111, 94-106	7.5	25
174	Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: a single-institution experience after a median follow-up of 95 months. *Annals of Surgical Oncology*, **2009**, 16, 893-9	3.1	25
173	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. *Radiotherapy and Oncology*, **2015**, 117, 315-21	5.3	24
172	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. *European Journal of Neurology*, **2013**, 20, 788-94	6	24

171	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. *Journal of Clinical Oncology*, **2017**, 35, 3531-3531	2.2	24
170	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. *Clinical Colorectal Cancer*, **2019**, 18, 125-132.e2	3.8	23
169	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. *PLoS ONE*, **2020**, 15, e0232449	3.7	23
168	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. *Targeted Oncology*, **2018**, 13, 227-234	5	23
167	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. *Critical Reviews in Oncology/Hematology*, **2012**, 81, 38-48	7	23
166	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. *Journal of Clinical Oncology*, **2015**, 33, 3508-3508	2.2	23
165	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. *British Journal of Cancer*, **2020**, 123, 403-409	8.7	22
164	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2020**, 19, 256-262.e2	3.8	22
163	The heterogeneous clinical and pathological landscapes of metastatic -mutated colorectal cancer. *Cancer Cell International*, **2020**, 20, 30	6.4	22
162	Oral anticancer drugs in the elderly: an overview. *Drugs and Aging*, **2007**, 24, 395-410	4.7	22
161	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. *Journal of Clinical Oncology*, **2019**, 37, 635-635	2.2	22
160	HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. *PLoS ONE*, **2015**, 10, e0144000	3.7	22
159	Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. *European Journal of Neurology*, **2013**, 20, 188-92	6	21
158	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. *European Journal of Cancer*, **2017**, 83, 106-115	7.5	21
157	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. *British Journal of Cancer*, **2019**, 121, 257-263	8.7	20
156	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. *Oncologist*, **2016**, 21, 600-7	5.7	20
155	Hepatoid adenocarcinoma of the colon: what should we target?. *Pathology and Oncology Research*, **2012**, 18, 93-6	2.6	20
154	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. *BMC Cancer*, **2017**, 17, 408	4.8	20

153	Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. *Journal of Clinical Oncology*, **2004**, 22, 3758-65	2.2	20
152	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. *Journal of Clinical Oncology*, **2013**, 31, 336-336	2.2	20
151	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). *Journal of Clinical Oncology*, **2021**, 39, 1108-1118	2.2	20
150	Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study. *Techniques in Coloproctology*, **2017**, 21, 633-640	2.9	18
149	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. *Oncotarget*, **2018**, 9, 7859-7866	3.3	18
148	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. *European Journal of Cancer*, **2019**, 109, 175-182	7.5	17
147	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*, **2020**, 25, 803-809	5.7	17
146	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. *Frontiers in Oncology*, **2019**, 9, 622	5.3	17
145	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. *Expert Opinion on Biological Therapy*, **2017**, 17, 1297-1308	5.4	17
144	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. *Journal of Clinical Oncology*, **2021**, 39, 631-641	2.2	17
143	Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 547-551	13.4	17
142	MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. *Pharmacogenomics Journal*, **2015**, 15, 219-25	3.5	16
141	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. *Clinical Colorectal Cancer*, **2020**, 19, 219-225	3.8	16
140	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. *Clinical Colorectal Cancer*, **2018**, 17, e395-e414	3.8	16
139	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. *Journal of Clinical Oncology*, **2016**, 34, TPS774-TPS774	2.2	16
138	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. *European Journal of Cancer*, **2017**, 77, 13-20	7.5	15
137	Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). *Cancer Management and Research*, **2019**, 11, 3631-3642	3.6	15
136	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. *Annals of Oncology*, **2015**, 26, 2503	10.3	15

135	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. *ESMO Open*, **2018**, 3, e000403	6	15
134	Chemotherapy for operable and advanced colorectal cancer. *Cancer Treatment Reviews*, **2009**, 35, 509-16	14.4	15
133	Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study. *Annals of Oncology*, **2007**, 18, 58-63	10.3	15
132	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. *European Journal of Cancer*, **2021**, 150, 155-167	7.5	15
131	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. *Oncologist*, **2019**, 24, 385-393	5.7	15
130	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. *British Journal of Cancer*, **2019**, 121, 593-599	8.7	14
129	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. *World Journal of Surgery*, **2015**, 39, 2500-9	3.3	14
128	Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: a first insight. *International Journal of Immunogenetics*, **2016**, 43, 32-9	2.3	14
127	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. *Liver International*, **2021**, 41, 1389-1397	7.9	14
126	Significance of pulmonary nodules in patients with colorectal cancer. *European Radiology*, **2012**, 22, 1680-6	3.6	13
125	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. *Drug Safety*, **2019**, 42, 159-179	5.1	13
124	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. *European Journal of Cancer*, **2019**, 110, 32-41	7.5	12
123	Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. *BMC Cancer*, **2020**, 20, 633	4.8	12
122	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. *British Journal of Cancer*, **2018**, 118, 878-886	8.7	12
121	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. *Cancer Chemotherapy and Pharmacology*, **2017**, 80, 599-608	3.5	12
120	Is intra-arterial chemotherapy useful in high-grade gliomas?. *Expert Review of Anticancer Therapy*, **2002**, 2, 507-19	3.5	12
119	Association of -3 rs1053004 and rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. *Frontiers in Pharmacology*, **2018**, 9, 367	5.6	11
118	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. *Digestive and Liver Disease*, **2019**, 51, 1713-1719	3.3	11

117	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. *Oncotarget*, **2016**, 7, 19781-93	3.3	11
116	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *British Journal of Cancer* , **2018**, 118, 955-965	8.7	10
115	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status **2019**, 7, 297		10
114	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. *British Journal of Cancer*, **2017**, 117, 1099-1104	8.7	10
113	5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. *Archives of Medical Research*, **2006**, 37, 860-5	6.6	10
112	PD-L1 expression in gastroesophageal dysplastic lesions. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 477, 151-156	5.1	10
111	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	10
110	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. *Expert Review of Clinical Pharmacology*, **2016**, 9, 877-85	3.8	10
109	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. *Translational Oncology*, **2019**, 12, 282-291	4.9	10
108	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. *Scientific Reports*, **2019**, 9, 11527	4.9	9
107	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. *Clinical Cancer Research*, **2020**, 26, 4485-4493	12.9	9
106	Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. *JAMA Oncology*, **2020**, 6, 927-929	13.4	9
105	Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. *International Journal of Cancer*, **2020**, 147, 3177-3188	7.5	9
104	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. *Medicine (United States)*, **2020**, 99, e19958	1.8	9
103	Multidisciplinary treatment of rectal cancer: medical oncology. *Annals of Oncology*, **2007**, 18, 1908-15	10.3	9
102	Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer. *Journal of Clinical Oncology*, **2007**, 25, 602-3; author reply 603	2.2	9
101	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. *JCO Precision Oncology*, **2021** , 5,	3.6	9
100	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. *ESMO Open*, **2019**, 4, e000489	6	8

99	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer*, **2019**, 19, 283	4.8	8
98	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. *Clinical Colorectal Cancer*, **2018**, 17, e601-e615	3.8	8
97	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. *Histopathology*, **2017**, 71, 1008-1011	7.3	8
96	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2020**, 26, 1017-1024	12.9	8
95	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. *Targeted Oncology*, **2020**, 15, 773-785	5	8
94	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. *Pharmacogenomics*, **2017**, 18, 197-200	2.6	7
93	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. *Clinical Cancer Research*, **2020**, 26, 4661-4669	12.9	7
92	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. *European Journal of Cancer*, **2020**, 130, 63-71	7.5	7
91	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).. *Journal of Clinical Oncology*, **2013**, 31, TPS3648-TPS3648	2.2	7
90	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. *Journal of Clinical Oncology*, **2021**, JCO2102008	2.2	7
89	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. *Cancers*, **2021**, 13,	6.6	7
88	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. *International Journal of Cancer*, **2020**, 147, 2303-2315	7.5	7
87	Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. *Journal of Geriatric Oncology*, **2019**, 10, 637-642	3.6	6
86	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. *European Journal of Cancer*, **2020**, 135, 230-239	7.5	6
85	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. *BMC Cancer*, **2018**, 18, 98	4.8	6
84	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*, **2017**, 2, e000241	6	6
83	Immune senescence and immune activation in elderly colorectal cancer patients. *Aging*, **2019**, 11, 3864-3875	5.6	6
82	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. *Journal of Clinical Oncology*, **2021**, 39, 58-58	2.2	6

81	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. *European Journal of Cancer*, **2021**, 146, 145-154	7.5	6
80	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. *Cancer Cell International*, **2018**, 18, 131	6.4	6
79	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. *European Journal of Cancer*, **2020**, 135, 78-88	7.5	5
78	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. *Investigational New Drugs*, **2018**, 36, 709-714	4.3	5
77	gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study. *Annals of Oncology*, **2016**, 27, vi559	10.3	5
76	Multidisciplinary treatment of rectal cancer: medical oncology. *Annals of Oncology*, **2007**, 18 Suppl 9, ix114-21	10.3	5
75	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 493-501	4.9	5
74	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		5
73	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. *British Journal of Cancer*, **2021**, 124, 183-190	8.7	5
72	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 144, 31-40	7.5	5
71	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. *Gastric Cancer*, **2020**, 23, 1064-1074	7.6	4
70	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. *Cancers*, **2020**, 12,	6.6	4
69	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. *Pharmacogenomics Journal*, **2018**, 18, 623-632	3.5	4
68	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients' Prognosis. *International Journal of Surgical Pathology*, **2019**, 27, 816-835	1.2	4
67	Cancer in the elderly. *Internal and Emergency Medicine*, **2011**, 6 Suppl 1, 115-8	3.7	4
66	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. *Journal of Personalized Medicine*, **2021**, 11,	3.6	4
65	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. *European Journal of Cancer*, **2020**, 133, 66-73	7.5	4
64	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. *Hpb*, **2021**, 23, 915-920	3.8	4

63	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. *Oncologist*, **2021**, 26, 302-309	5.7	4
62	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. *Journal of the National Cancer Institute*, **2021**,	9.7	4
61	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102583	2.2	4
60	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. *Clinical Colorectal Cancer*, **2019**, 18, 269-279.e5	3.8	3
59	The Italian Rare Pancreatic Exocrine Cancer Initiative. *Tumori*, **2019**, 105, 353-358	1.7	3
58	Ramucirumab: the long and winding road toward being an option for mCRC treatment. *Expert Opinion on Biological Therapy*, **2019**, 19, 399-409	5.4	3
57	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. *PLoS ONE*, **2018**, 13, e0193640	3.7	3
56	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.. *European Journal of Cancer*, **2021**, 161, 90-98	7.5	3
55	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial **2016**,		3
54	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study **2021**, 9,		3
53	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. *PLoS ONE*, **2020**, 15, e0239439	3.7	3
52	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. *European Journal of Cancer*, **2020**, 139, 81-89	7.5	3
51	Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. *Cancers*, **2020**, 12,	6.6	3
50	Another Chapter of the : Is Primary Tumor Location a Prognostic Feature in Mutant Metastatic Colorectal Cancer?. *Oncologist*, **2019**, 24, e77-e79	5.7	3
49	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Supportive Care in Cancer*, **2021**, 29, 3971-3980	3.9	3
48	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 2505-2514	12.9	3
47	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. *European Journal of Cancer*, **2021**, 155, 73-84	7.5	3
46	An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. *Expert Review of Respiratory Medicine*, **2019**, 13, 635-644	3.8	2

45	Genetic Variants of the Gene, Telomere Length, and Circulating as Prognostic Markers in Rectal Cancer Patients. *Cancers*, **2020**, 12,	6.6	2
44	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. *Cancers*, **2020**, 12,	6.6	2
43	Bone metastases in biliary cancers: A multicenter retrospective survey. *Journal of Bone Oncology*, **2018**, 12, 33-37	4.5	2
42	QoL is a cool tool. *Annals of Oncology*, **2017**, 28, 2032-2033	10.3	2
41	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. *Annals of Oncology*, **2014**, 25, 2443-2444	10.3	2
40	Phase II Single-Agent Studies in Elderly Cancer Patients. *Tumori*, **2002**, 88, S13-S14	1.7	2
39	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. **2022**, 10,		2
38	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.. *Cancer Management and Research*, **2021**, 13, 9379-9389	3.6	2
37	Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.. *Journal of Clinical Oncology*, **2019**, 37, 202-202	2.2	2
36	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. *Biomedicines*, **2021**, 9,	4.8	2
35	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. *British Journal of Cancer*, **2021**, 125, 839-845	8.7	2
34	Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. *Tumori*, **2021**, 107, 46-54	1.7	2
33	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		2
32	Phase II single-agent studies in elderly cancer patients. *Tumori*, **2002**, 88, S13-4	1.7	2
31	Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. *Tumori*, **2013**, 99, 596-600	1.7	2
30	Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. *Tumori*, **2019**, 105, 243-252	1.7	1
29	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835919899850	5.4	1
28	New perspectives for TAS-102: TASK successful?. *Lancet Oncology, The*, **2017**, 18, 1139-1141	21.7	1

27	An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.. *Current Oncology*, **2022**, 29, 544-550	2.8	1
26	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. *Targeted Oncology*, **2021**, 16, 517-527	5	1
25	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. *European Journal of Cancer*, **2021**, 153, 16-26	7.5	1
24	Interaction via Wnt/B-Catenin Is Associated with Patients' Survival in HER2-Positive Metastatic Gastric Adenocarcinoma.. *Cancers*, **2022**, 14,	6.6	1
23	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.. *European Journal of Cancer*, **2022**, 166, 165-175	7.5	1
22	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. *Acta Oncologica*, **2018**, 57, 412-419	3.2	0
21	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. *Oncologist*, **2022**, 27, e29-e36	5.7	0
20	Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology.. *Patient Preference and Adherence*, **2022**, 16, 353-362	2.4	0
19	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. *European Journal of Cancer*, **2021**, 148, 190-201	7.5	0
18	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. *Pharmacogenomics Journal*, **2021**, 21, 285-295	3.5	0
17	BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications.. *Critical Reviews in Oncology/Hematology*, **2022**, 103647	7	0
16	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.. *European Journal of Cancer*, **2022**, 167, 81-91	7.5	0
15	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. *European Journal of Cancer*, **2022**, 167, 23-31	7.5	0
14	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.. *European Journal of Cancer*, **2022**, 168, 34-40	7.5	0
13	Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.. *JCO Precision Oncology*, **2022**, 6, e2200037	3.6	0
12	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 42, 1-14	7.1	0
11	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. *European Journal of Cancer*, **2022**, 170, 64-72	7.5	0
10	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. *Cancers*, **2022**, 14, 2568	6.6	0

9	An untreatable dyspnoea: more defendants under investigation. *Internal and Emergency Medicine*, **2017**, 12, 199-205	3.7
8	Adjuvant systemic chemotherapy with 5-fluorouracil and leucovorin in colon cancer: a monoinstitutional institutional experience. *Immunopharmacology and Immunotoxicology*, **2008**, 30, 235-42	3.2
7	Treatment of advanced breast cancer in elderly women: medical approach. *Aging Health*, **2008**, 4, 267-277	
6	Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?. *Journal of Clinical Oncology*, **2006**, 24, 4668-9; author reply 4669	2.2
5	Chemotherapy in brain metastases of lung and breast cancer. *Therapy: Open Access in Clinical Medicine*, **2004**, 1, 101-110	
4	Colon cancer in elderly patients: what is the best treatment?. *Aging Health*, **2008**, 4, 279-286	
3	Multidisciplinary management is strongly suggested in elderly patients with rectal carcinoma. *Aging Health*, **2008**, 4, 287-298	
2	In Reply. *Oncologist*, **2016**, 21, e5-e6	5.7
1	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. *Medical Oncology*, **2021**, 38, 17	3.7